Hepatic decompensating events in patients with type 2 diabetes with and without alcohol or tobacco use disorders (Comparison between propensity-score matched cohorts)

Cohort size	Exposure cohort	Comparison cohort	# of cases (overall risk) (Exposure cohort)) # of cases (overall risk) (Comparison cohort)			HR (95% CI)
	No alcohol or tobbaco use disord	ers					
41,905	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	259 (0.62%)	1,432 (3.42%)	⊢■⊣		0.17 (0.15–0.20)
40,910	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	1,106 (2.70%)	1,241 (3.03%)		⊦ ■- I	0.91 (0.84–0.99)
90,983	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	1,907 (2.11%)	2,630 (2.91%)		I ≡ I	0.67 (0.63-0.71)
46,475	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	1,048 (2.26%)	1,164 (2.51%)		 ■ 	0.86 (0.79-0.94)
81,938	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	1,791 (2.19%)	2,426 (2.96%)		H	0.70 (0.66–0.74)
55,352	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	1,134 (2.05%)	1,282 (2.32%)		⊦ = ⊦	0.84 (0.77–0.91)
	Alcohol or tobbaco use disorder	rs					
4,515	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	43 (0.95%)	209 (4.63%)			0.20 (0.14–0.28)
5,253	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	263 (5.01%)	287 (5.46%)		⊢ ■	0.94 (0.79–1.11)
12,126	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	465 (3.84%)	617 (5.09%)		⊢■⊢	0.70 (0.62-0.79)
6,566	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	288 (4.39%)	290 (4.42%)		⊢ ■	0.95 (0.80–1.11)
11,206	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	436 (3.89%)	568 (5.07%)		⊢■⊣	0.73 (0.64–0.82)
7,032	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	256 (3.64%)	308 (4.38%)		⊢■	0.78 (0.66–0.92)
					0.20 0.30	0.50 0.70 1.0 Hazard Ratio (HR)	2.0 3.00 4.0